Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.73 +3.01%

+$0.81 today

Market cap
$1.81B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 5.16M

Average 1.81M

RARE Account Payables

Amounts the company owes suppliers for goods and services received.

Ultragenyx Pharmaceutical Inc.NASDAQ: RARE

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables falls 11.5% from a year ago

Account payables stood at $42M at the end of Q1 FY2026, down 11.5% from a year earlier and up 35.5% from the prior quarter. Over 3 fiscal years it compounded at -10.5% a year.

Context

  • Account payables amounted to 3.2% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
  • Account payables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -11.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$42M+35.5% QoQ
Last fiscal yearDec 2025
$31M-20.0% YoY
Year agoMar 2025
$47.45M-11.5% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.5%——
1 year-20.0%——
3-year CAGR-10.5%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
31M USD
Year-over-year change
-20.0%
4-year CAGR
+16.0%

Account Payables vs competitors

How RARE compares with its peers on the latest reported figures

  • RARE's Mar 2026 account payables of $42M is the highest of the 11 companies compared; the peer median is $9.55M.
  • Its year-over-year change of -11.5% is the 6th highest of 11, against a peer median of -6.2%.
  • Account payables amounts to 3.2% of total assets for RARE, versus a peer median of 2.1%.
RARE Competitors Peer median
Account Payables for RARE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RAREUltragenyx Pharmaceutical Inc.Mar 2026$42M -11.5%-10.5%3.2%
PTCTPTC Therapeutics, Inc.Jun 2026$40.45M +52.6%+18.6%1.2%
BBIOBridgeBio Pharma, Inc.Jun 2026$27.2M +4.1%+46.3%2.2%
RGNXREGENXBIO Inc.Mar 2026$21.21M +11.4%-7.8%6.2%
MGTXMeiraGTx Holdings plcMar 2026$16.66M -17.9%-15.4%6.8%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$14.69M +253.9%+49.8%2.9%
QUREuniQure N.V.Mar 2026$4.4M -16.5%-22.2%0.6%
ABEOAbeona Therapeutics Inc.Mar 2026$4.07M -18.9%+63.3%2.1%
MREOMereo BioPharma Group plcMar 2026$3.23M +10.3%-27.5%7.9%
BMRNBioMarin Pharmaceutical Inc.Sep 2026$0 -100.0%+10.6%0.0%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$0 -100.0%—0.0%
Peer median (excluding RARE) $9.55M-6.2%+10.6%2.1%

Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents307.58M132.94M213.58M173.73M434M
Short-term Investments432.61M614.82M363.63M436.3M259M
Net Receivables44.43M40.45M73.39M121.8M159M
Inventory16.23M26.77M33.97M45.01M52M
Other Current Assets55.75M68.93M47.62M40.29M47M
Total Current Assets856.6M883.9M732.18M817.12M951M
Property, Plant & Equipment (Net)176.18M259.73M290.57M265.93M267M
Goodwill44.41M44.41M44.41M44.41M44M
Intangible Assets130.79M160.11M166.27M178.31M176M
Long-term Investments293.86M148.97M199.9M135M59M
Tax Assets00000
Other Non-current Assets20.56M48.34M57.69M62.68M35M
Total Non-current Assets665.79M661.55M758.83M686.33M581M
Total Assets1.52B1.55B1.49B1.5B1.53B
Account Payables17.14M43.27M42.11M38.76M31M
Short-term Debt000081M
Tax Payables00000
Deferred Revenue7.61M1.48M000
Other Current Liabilities00142.79M87.47M183M
Total Current Liabilities181.37M261.21M280.44M344.15M384M
Long-term Debt00001.17B
Deferred Tax Liabilities33.31M31.67M30.06M30.06M30M
Deferred Revenue (Non-current)1.47M0000
Other Non-current Liabilities352.79M880.26M874.53M836.91M(4M)
Total Non-current Liabilities418.47M931.74M935.16M897.01M1.22B
Total Liabilities599.84M1.19B1.22B1.24B1.61B
Common Stock69K70K82K92K0
Retained Earnings(2.07B)(2.78B)(3.39B)(3.96B)(4.53B)
Accumulated OCI(1.4M)(6.57M)647K(643K)1M
Other Stockholders Equity00432K3.59M8M
Minority Interest0007M7M
Total Equity922.56M352.49M275.41M262.3M(73M)
Total Debt41.97M31.59M43.17M40.34M1.28B
Net Debt(265.61M)(101.35M)(170.42M)(133.39M)842M

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Intrinsic Alpha fair value

Locked

Current Price

$17.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.